Korean Circ J.  2020 Oct;50(10):949-950. 10.4070/kcj.2020.0328.

Lipid and Ischemic Heart Disease Revisited: Mendelian Randomization Analysis

• Sung J

• KMID: 2507013
• DOI: http://doi.org/10.4070/kcj.2020.0328

Reference

1. Jun JE. Cholesterol lowering therapy in coronary artery disease: with particular reference to statins. Korean Circ J. 2001; 31:849–856.

2. Sung J. The long and winding road: to the proper understanding of high-density lipoprotein. Korean Circ J. 2020; 50:248–249. PMID: 32100481.

3. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMID: 30002074.

4. Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008; 5:e52. PMID: 18318597.

5. Spiller W, Jung KJ, Lee JY, Jee SH. Precision medicine and cardiovascular health: insights from mendelian randomization analyses. Korean Circ J. 2020; 50:91–111. PMID: 31845553.

6. Lee SH, Lee JY, Kim GH, et al. Two-sample mendelian randomization study of lipid levels and ischemic heart disease. Korean Circ J. 2020; 50:940–948.

7. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013; 178:1177–1184. PMID: 23863760.

8. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44:512–525. PMID: 26050253.